Patients with change >0.5 from baseline in erosion and joint space narrowing scores of the hands and feet at week 102
| Assessment variable | MTX-only | 3 mg/kg Infliximab+MTX | 10 mg/kg Infliximab+MTX | Total infliximab | ||
|---|---|---|---|---|---|---|
| q 8 Weeks | q 4 Weeks | q 8 Weeks | q 4 Weeks | |||
| Results are shown as No (%) of patients unless indicated otherwise. | ||||||
| Patients with early RA (n) | 17 | 19 | 19 | 20 | 7 | 65 |
| Patients evaluated (n) | 12 | 10 | 16 | 17 | 6 | 49 |
| Erosion score | ||||||
| Total erosion score >0.5 | 10 (83) | 1 (10) | 6 (38) | 6 (35) | 2 (33) | 15 (31) |
| p Value v placebo | 0.002 | 0.023 | 0.022 | 0.107 | 0.002 | |
| Hands | 8 (67) | 2 (20) | 3 (19) | 5 (29) | 2 (33) | 12 (24) |
| p Value v placebo | 0.043 | 0.019 | 0.067 | 0.321 | 0.013 | |
| Feet | 10 (83) | 2 (20) | 2 (13) | 4 (24) | 1 (17) | 9 (18) |
| p Value v placebo | 0.008 | <0.001 | 0.003 | 0.013 | <0.001 | |
| Joint space narrowing | ||||||
| Total joint space narrowing >0.5 | 10 (83) | 4 (40) | 4 (25) | 6 (35) | 1 (17) | 15 (31) |
| p Value v placebo | 0.074 | 0.006 | 0.022 | 0.013 | <0.002 | |
| Hands | 8 (66) | 4 (40) | 4 (25) | 3 (18) | 1 (17) | 12 (24) |
| p Value v placebo | 0.391 | 0.053 | 0.018 | 0.131 | 0.013 | |
| Feet | 8 (67) | 2 (20) | 1 (6) | 4 (24) | 0 (0) | 7 (14) |
| p Value v placebo | 0.043 | 0.001 | 0.029 | 0.013 | <0.001 | |